Glycan-Based Antidiabetic Drug Development Services
Ace Therapeutics is committed to applying our expertise and platform technologies to help clients develop promising glycan-based antidiabetic drugs. Our experienced team of professionals can provide comprehensive process support from target discovery to preclinical evaluation to help clients accelerate the development of innovative antidiabetic drugs.
Introduction of Glycan-Based Antidiabetic Drugs
Glycan-based antidiabetic drugs provide diverse treatment options for the diabetic population. A range of drugs based on different glycan structures, such as acarbose and voglibose, have been developed and applied in diabetes management. In addition, a number of drugs based on glycan molecules with different structures, have shown potential in diabetes treatment. For example, beta-glucan can be used as a bioactive macromolecule to help control type 2 diabetes with minimal side effects.
Fig. 1 Acarbose mechanism of action: competitive inhibition of the intestinal enzymatic hydrolysis of oligosaccharides. (Rosak, C. and Gabriele M., 2012)
Our Glycan-Based Antidiabetic Drug Development Services
With the scientific community's deeper understanding of the pathomechanisms of diabetes and the structure-function relationships of glycan molecules, we are able to design glyco-drugs with greater precision and conduct more targeted preclinical evaluations. Ace Therapeutics is committed to applying our expertise to help our clients develop more highly effective, innovative glycan-based antidiabetic drugs with fewer side effects.
We are dedicated to offering clients comprehensive support throughout the following two pivotal development phases.
Glycan-Based Antidiabetic Drug Discovery Services
- Target discovery and validation
Our expertise in the study of diabetes pathogenesis allows us to provide target-based drug discovery services to our clients. Through in-depth study of enzymes, receptors and signaling pathways related to diabetes mechanisms, we can screen and validate druggable targets for subsequent drug development.
- Glycoside compound library construction and optimization
We can utilize your existing glycosylated compound library or assist you in building a new compound library for subsequent screening of glycan based antidiabetic drugs.
- High-throughput screening and activity validation
Ace Therapeutics utilizes advanced high-throughput screening technology to efficiently evaluate potential glycan-based antidiabetic drugs. Furthermore, we assess the efficacy and activity of potential compounds through comprehensive analysis to confirm their viability as antidiabetic agents.
Preclinical Development Services for Glycan-Based Antidiabetic Drugs
- Preclinical efficacy assessment
We use ex vivo and in vivo models to fully assess the efficacy of potential glycan-based antidiabetic drugs. This typically involves testing the effects of candidates on glycemic control, insulin sensitivity, pancreatic beta cell function, and potential therapeutic effects on diabetic complications.
We combine animal models with a variety of advanced analytical techniques to help our clients fully evaluate the absorption, distribution, metabolism, and excretion characteristics of their glycan-based antidiabetic drug candidates.
- Preclinical toxicology and safety assessment
Comprehensive short- and long-term toxicity assessments, reproductive toxicity assessments to evaluate the safety of candidates.
Our Capabilities and Technology Platforms
- Target-based drug screening platform: Comprehensive drug screening platform covering diabetes-related enzymes, receptors and signaling pathway targets has been established.
- In vitro and in vivo efficacy evaluation platform: Cell, tissue or animal model-based efficacy evaluation services.
- Early druggability screening and evaluation platform: Early ADME, PK studies, and off-target effect screening.
Ace Therapeutics' interdisciplinary team of experts is dedicated to providing comprehensive preclinical solutions to ensure that our clients receive the most specialized and refined support in glycan-based antidiabetic drugs development. For more details, please contact us and we will be glad to help you.
References
- Wan, Y. J. et al. A review on the structure and anti-diabetic (type 2) functions of β-glucans. Foods. 11.1 (2021): 57.
- Rosak, C. and Gabriele M. "Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations." Diabetes, metabolic syndrome and obesity: targets and therapy. (2012): 357-367.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
